Merus NVNASDAQ:MRUS
- LAST PRICE51.0350
- TODAY'S CHANGE (%)1.1750 (2.3566%)
- Bid / Lots50.9700/ 1
- Ask / Lots51.1000/ 4
- Open / Previous Close50.0600 / 49.8600
- Day Range
- 52 Week Range
- Volume109,382
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MRUS |
|---|---|---|
| 09:32 ET | 3638 | 50.08 |
| 09:34 ET | 200 | 50.1 |
| 09:39 ET | 750 | 50.61 |
| 09:41 ET | 100 | 50.875 |
| 09:43 ET | 400 | 50.76 |
| 09:45 ET | 500 | 50.76 |
| 09:48 ET | 1872 | 50.755 |
| 09:50 ET | 600 | 50.84 |
| 09:52 ET | 200 | 50.745 |
| 09:54 ET | 207 | 50.745 |
| 09:56 ET | 400 | 50.73 |
| 09:57 ET | 200 | 50.795 |
| 09:59 ET | 600 | 50.79 |
| 10:01 ET | 2717 | 50.64 |
| 10:03 ET | 1749 | 50.435 |
| 10:10 ET | 843 | 50.295 |
| 10:12 ET | 100 | 50.12 |
| 10:15 ET | 300 | 50.46 |
| 10:21 ET | 272 | 50.5 |
| 10:30 ET | 200 | 50.16 |
| 10:32 ET | 299 | 50.16 |
| 10:33 ET | 100 | 50.06 |
| 10:35 ET | 100 | 50.16 |
| 10:37 ET | 100 | 50.06 |
| 10:39 ET | 241 | 50.1803 |
| 10:42 ET | 2700 | 50.355 |
| 10:44 ET | 400 | 50.28 |
| 10:51 ET | 300 | 50.36 |
| 10:57 ET | 200 | 50.3 |
| 11:00 ET | 100 | 50.42 |
| 11:02 ET | 844 | 50.51 |
| 11:04 ET | 100 | 50.405 |
| 11:06 ET | 200 | 50.41 |
| 11:08 ET | 200 | 50.415 |
| 11:11 ET | 100 | 50.42 |
| 11:15 ET | 100 | 50.34 |
| 11:20 ET | 100 | 50.3 |
| 11:22 ET | 227 | 50.15 |
| 11:24 ET | 300 | 50 |
| 11:26 ET | 100 | 50.015 |
| 11:27 ET | 2900 | 50.2 |
| 11:29 ET | 600 | 50.23 |
| 11:31 ET | 400 | 50.31 |
| 11:33 ET | 200 | 50.41 |
| 11:40 ET | 100 | 50.5 |
| 11:42 ET | 300 | 50.395 |
| 11:45 ET | 1529 | 50.505 |
| 11:51 ET | 300 | 50.455 |
| 11:56 ET | 100 | 50.55 |
| 12:03 ET | 1189 | 50.59 |
| 12:09 ET | 200 | 50.565 |
| 12:18 ET | 800 | 50.59 |
| 12:20 ET | 300 | 50.64 |
| 12:21 ET | 100 | 50.7 |
| 12:25 ET | 100 | 50.67 |
| 12:27 ET | 400 | 50.645 |
| 12:32 ET | 100 | 50.71 |
| 12:34 ET | 100 | 50.635 |
| 12:38 ET | 100 | 50.635 |
| 12:39 ET | 300 | 50.67 |
| 12:43 ET | 100 | 50.77 |
| 12:45 ET | 100 | 50.75 |
| 12:52 ET | 100 | 50.675 |
| 12:54 ET | 100 | 50.675 |
| 12:56 ET | 200 | 50.64 |
| 12:57 ET | 300 | 50.685 |
| 01:01 ET | 300 | 50.72 |
| 01:08 ET | 100 | 50.7 |
| 01:12 ET | 700 | 50.81 |
| 01:15 ET | 980 | 50.83 |
| 01:19 ET | 100 | 50.83 |
| 01:24 ET | 700 | 50.79 |
| 01:30 ET | 100 | 50.84 |
| 01:32 ET | 600 | 50.795 |
| 01:35 ET | 600 | 50.75 |
| 01:37 ET | 100 | 50.75 |
| 01:39 ET | 401 | 50.7 |
| 01:44 ET | 300 | 50.75 |
| 01:51 ET | 800 | 50.77 |
| 01:53 ET | 200 | 50.71 |
| 02:00 ET | 200 | 50.73 |
| 02:02 ET | 100 | 50.72 |
| 02:04 ET | 400 | 50.725 |
| 02:06 ET | 200 | 50.72 |
| 02:09 ET | 600 | 50.74 |
| 02:11 ET | 100 | 50.755 |
| 02:13 ET | 200 | 50.78 |
| 02:20 ET | 100 | 50.79 |
| 02:26 ET | 300 | 50.81 |
| 02:27 ET | 24800 | 50.925 |
| 02:29 ET | 100 | 50.915 |
| 02:33 ET | 1100 | 50.915 |
| 02:36 ET | 2522 | 51.03 |
| 02:38 ET | 100 | 51.035 |
| 02:40 ET | 200 | 51.035 |
| 02:42 ET | 300 | 51.0999 |
| 02:44 ET | 100 | 51.035 |
Oct 1, 2024
DJ Merus Is Maintained at Buy by Guggenheim, from 1:19PM ET on Tuesday Oct 01, 2024 by Dow Jones
1:19PM ET on Tuesday Oct 01, 2024 by Dow Jones
Sep 30, 2024
Sep 17, 2024
Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024, from 9:00AM ET on Tuesday Sep 17, 2024 by Dow Jones
9:00AM ET on Tuesday Sep 17, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Merus NV | 3.4B | -17.8x | --- |
Dyne Therapeutics Inc | 3.4B | -9.1x | --- |
Apogee Therapeutics Inc | 3.3B | -24.3x | --- |
MoonLake Immunotherapeutics | 3.3B | -59.4x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Alvotech SA | 3.7B | -4.6x | --- |
Company Information
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
Contact Information
- Headquarters
- Uppsalalaan 17, 3rd & 4th floorUTRECHT, Netherlands 3584 CT
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Anand Mehra
- President, Chief Executive Officer, Executive Director
- Sven Lundberg
- Chief Financial Officer
- Gregory Perry
- Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
- Peter Silverman
- Chief Medical Officer
- Fabian Zohren
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.4B |
|---|---|
Revenue (TTM) | $35.2M |
Shares Outstanding | 68.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.12 |
EPS | $-2.87 |
Book Value | $6.16 |
P/E Ratio | -17.8x |
Price/Sales (TTM) | 96.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -560.03% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
